Our approach is anchored in our deep experience in discovering and developing innovative gram-negative product candidates
At Achaogen, to discover and develop gram-negative product candidates, we rely on novel techniques, deep knowledge and expert capabilities.
Our Antibiotic Discovery and Development Engine
Knowledge of gram-negative antibiotic chemistry enables us to engineer the chemical structure of molecules to avoid resistance mechanisms and to penetrate the double membranes of gram-negative pathogens.
Specialized chemistry libraries are designed to contain compounds that have the necessary properties for penetration of gram-negative bacteria and are used in screening campaigns against clinical isolates of MDR gram-negative pathogens.
Use of nonclinical data to predict clinical outcomes to predict the clinical efficacy of our early developmental candidates.
Microbiology capabilities in clinically important gram-negative pathogens allows us to rapidly validate new antibacterial targets, determine the mode of action of our new agents, and progress promising molecules to advanced testing.
Collaborations with industry-leading and scientific experts in antibacterial drug development and the field of antibiotic pharmacology, provides us with access to leading information and advice.
Development of a state-of-the-art antibody discovery platform may enable us to enrich and select extremely rare and potent neutralizing antibodies that have exquisite specificity for target antigens.